Patrick Daly

DocwireNews

In the ZEPHYR 2 trial, researchers evaluated real-world outcomes and the long-term impact of benralizumab among patients with severe eosinophilic asthma and differing clinical characteristics. This was the largest real-world study on benralizumab according to the study&rsquo;s lead author, Donna Carstens.According to the <a href="https://www.jacionline.org/article/S0091-6749(21)01910-2/fulltext" target="_blank" rel="noopener">article</a>, published in&nbsp;The Journal of Allergy and Clinical Immunology: In Practice, benralizumab induced &ldquo;significantly improved asthma control&rdquo; in real-world patients, including those who switched from other biologic treatments, were treated for up to 24 months, or had blood eosinophil levels counts ranging from &lt;150 cells/&mu;l to &ge;300 cells/&mu;l.Researchers enrolled 429 patients who had 2 or more exacerbations during the 12 months before their benralizumab start date, which was used as the index. Treatments took place from November 2017 to June 2019, and patients were evaluated via medical, laboratory, and pharmacy US insurance claims data.<h3>Benralizumab Impact on Asthma Exacerbation Rate</h3>The primary end point was exacerbation rate in the 12 months after indexing compared with the previous 12 months. Patient subgroups included those who switched from a previous biologic (n=349), had longer-term follow-up of 18 to 24 months (n=419), or had blood eosinophil counts of &lt;150, &ge;150, 150-299, &lt;300, and &ge;300 cells/&mu;l.Reportedly, benralizumab decreased exacerbation rates from a pre-index range of 3.10-3.55 per patient year (PPY) to a post-index range of 1.1-1.72 PPY across all blood eosinophil count subgroups, representing a 52% to 64% decrease (P&lt;.00).Researchers observed similar reductions of 3.25 to 1.25 PPY (62%) and 3.81 to 1.78 PPY (53%) among patients who switched to benralizumab from omalizumab or mepolizumab, respectively. Patients with extended follow-up demonstrated comparable decreases after 18 months (3.38 to 1.18 PPY; 65%) or 24 months (3.38 to 1.08 PPY; 68%) of treatment (P&lt;0.001). The authors noted 39% and 49% of these patients had no exacerbations in months 0-12 and 12-24 post-index, respectively.The study&rsquo;s authors ultimately suggested the real-world data supported the efficacy of benralizumab for achieving asthma symptom control across differing subgroups of patients with severe eosinophilic asthma.&ldquo;These findings support benralizumab as a valuable therapeutic option in the management of severe eosinophilic asthma,&rdquo; they closed.View More <a href="https://www.docwirenews.com/asthma-resource-center/">News and Research on the Asthma Resource Center</a>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Benralizumab in Real-World Severe Eosinophilic Asthma

Asthma

In the ZEPHYR 2 trial, researchers assessed benralizumab in patients with variations of severe eosinophilic asthma.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe